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Scaffolding of Disrupted Vessel Wall*
Patrick W. Serruys, MD, PHD,y Pannipa Suwannasom, MD,z Shimpei Nakatani, MD,z Yoshinobu Onuma, MD, PHDzT he advance of coronary stent technology andscaffolding devices in coronary interventionprocedures aims at reducing both short-
term and long-term adverse cardiac events. However,
periprocedural myocardial infarction (PMI) still occurs
during the coronary procedure. In the report by Kawa-
moto et al. (1) in this issue of JACC: Cardiovascular
Interventions, the investigators present the clinical
impact of “average” abluminal strut surface area
(ASSA) on PMI (based on extended historical MI deﬁni-
tion) and long-term clinical outcome. The results from
this group showed that compared with the Cypher
stent (Cordis, Johnson and Johnson, Warren, New Jer-
sey) with an ASSA of 67 mm2, the Absorb device
(Abbott Vascular, Santa Clara, California) has a larger
ASSA of 133 mm2 and is associated with PMI rates
twice as high as those in Cypher group. There was no
signiﬁcant difference in long-term clinical outcomes
between the 2 devices.SEE PAGE 900The results of the present study may warrant a
word of caution in interpretation. First, the pro-
pensity analysis can lead to misleading statements.
Previously, it has been suggested in a propensity
matched nonrandomized comparison conducted by
our group that Absorb bioresorbable vascular scaffold
was associated with a higher incidence of post-
procedural side branch occlusion (SBO) compared*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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paper to disclose.with the metallic everolimus-eluting stent. The dif-
ference was more pronounced with small side
branches with a reference vessel diameter #0.5 mm
(2). However, there was no signiﬁcant difference in
the incidence of post-procedure creatine kinase-
myocardial band elevation. The hypothesis has been
tested again in the ABSORB II (ABSORB II Random-
ized Controlled Trial: A Clinical Evaluation to
Compare the Safety, Efﬁcacy, and Performance of
Absorb Everolimus Eluting Bioresorbable Vascular
Scaffold System Against Xience Everolimus Eluting
Coronary Stent System in the Treatment of Subjects
With Ischemic Heart Disease Caused by De Novo
Native Coronary Artery Lesion) randomized control
trial (3) in which all 3 cardiac biomarkers were
explored and analyzed in a core lab. There was no
signiﬁcant difference in the normalized value for each
enzyme. To our surprise, the randomized data
showed that the SBO (core lab analysis) occurred
more often in the metallic stent group (39 of 503
side branches [8%]) than in the bioresorbable scaf-
fold group (52 of 998 side branches [5%]), but this
difference did not reach a statistical signiﬁcance,
p ¼ 0.07.
Second, despite their hypothesis that greater ASSA
is associated with PMI rate, mechanical complications
such as SBO were not reported. SBO should be
assessed rigorously by an independent core lab using
quantitative coronary angiography whenever possible
(e.g., side branch diameter $0.5 mm, the lower limit
of automated edge detection).
Finally, it is unclear whether the cardiac bio-
markers were systematically obtained. Generally, the
incidence of PMI depends on the availability, type of
post-procedural cardiac biomarkers, and enzymatic
criteria used, as well as the frequency of cardiac bio-
markers sampling. PMI remains a debatable issue
with a heterogeneous incidence due to a diversity of
deﬁnitions. The incidence of PMI could vary from 1%
FIGURE 1 Strut Width: Absorb Versus Xience Stent
(A, E) The yellow, blue, and green vertical lines correspond to the various levels of the optical coherence tomography cross-section of Absorb
(B to D) and Xience stent (F to H) showing the various degrees of embedment of the 2 respective devices. B and F demonstrate the strut width
at the hinges level. The hinge strut width (yellow double-headed arrow) of the Absorb scaffold (B) can measure up to 883 mm, whereas
the strut of the Xience stent (F) is only 428 mm. C and G demonstrate strut width at the ring and link level. The ring strut width is represented
with blue line and link strut width is labeled by a blue bracket. E and H demonstrate strut width at the crown peak level with a green arrow,
and the link strut width is labeled by a green bracket.
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911to 32% (3). For example, cardiac troponin T for the
third universal deﬁnition can lead to overestimation
of PMI. Ideally, an assessment of 3 cardiac biomarkers
is recommended.
Nevertheless, the study results could put forward
some new mechanical and rheological hypotheses.
The implantation of a device with a large “footprint”
could potentially cause small SBO and subsequent
cardiac biomarkers to rise. One can speculate that the
large footprint of the ABSORB (scaffold area covers
26% to 32% of the vessel wall area) could accidentally
cover the ostium of small side branches, resulting in
SBO. When measured using optical coherence to-
mography, the width of the Absorb struts at the
hinge point can be as large as 800 mm (Figure 1).
Therefore, a side branch with a diameter of <0.8 mm
could be occluded by the device (Figure 2B). The
width of the strut could also inﬂuence the embed-
ment of the strut. When the same force is applied, a
device with a smaller contact area would generate a
higher pressure to the vessel wall according to thesimple principle: Pressure ¼ Force/Area (Figures 2C
and 2D). Taking into account the fact that a more
aggressive post-dilation was applied in the Cypher
group, the Cypher stent may have been more
embedded (Figure 2E) into the vessel wall than the
Absorb device was (Figure 2F). Embedded struts
imply penetration of the cutting edge of the metals
through ﬁbrous, calciﬁc, and necrotic plaques. The
deep penetration of the strut into the vessel wall
could also disrupt and displace the edge of the
ostium of a side branch, with possible reduction or
occlusion of its ostium (Figure 2A); additionally
injury of the necrotic core can squeeze microparti-
cles, which results in distal embolization and rise in
cardiac biomarkers (4).
On the other hand, the thick protruding strut of the
Absorb disrupts the laminar ﬂow and induces ﬂow
disturbances. In a ﬂow simulation of a microenvi-
ronment computed by optical coherence tomography/
angiography fusion in a human coronary artery (5),
the relatively high shear stress on top of the
FIGURE 2 Possible Mechanisms of PMI in Relation With Strut Width and Height
Strut width and side branch occlusion (SBO): (A) A deep embedment of metallic struts can displace plaque underneath (yellow) toward
the ostium of side branch in the close vicinity of the strut (red dotted line), resulting in SBO. A narrow strut (small footprint) enables strut
penetration through the vessel wall and more likely to create an injury than a wide strut when the same force was applied (e.g., intrastent
dissection) (white arrow) Conversely, SBO may result from the large footprint of the Absorb scaffold strut (B). For instance, the Absorb
strut at the hinge has a strut width of 833 mm (yellow arrow) and may be even larger than the ostium of side branch beneath (708 mm,
green dotted line). Strut width and embedment: The color coded stress strain graphics in C and D show the pressure (light blue) trans-
mitted to the vessel wall by the 2 devices with different surface scaffold areas. In C, the scoring balloon (LacrosseNSE, Goodman, Nagoya,
Japan) has a small surface area; as a consequence, the pressure exerted by the membrane of the balloon on the vessel wall (dark blue)
is very topical and “penetrating,” whereas the large rectangular strut of the scaffold (D) has a diffuse pattern of the stress strain rela-
tionship. In order to achieve similar expansion (and penetration) of both devices, more force should be applied on the large footprint of
the scaffold (F, snowshoe) than on the narrow footprint (E, ice skate) of the metallic stent. Strut width, embedment, and endothelial
shear stress: The footprint of the Cypher (G) is more easily embedded into the vessel wall than that of the wide Absorb strut (H).
The Cypher embedded strut does not disturb the lamina ﬂow substantially whereas the Absorb strut protrudes more into the lumen,
thereby creating high endothelial shear stress (ESS) on top of the struts, resulting in platelet activation. Behind the protruding strut,
the ﬂow reversal that creates low ESS results in local aggregation of activated platelet and promotes the thrombogenic process.
Modiﬁed with permission from Koskinas et al. (7) and Jimenez et al. (6). Red stars represent activated platelets; red lines represent
quiescent platelets. A ¼ area; ADP ¼ adenosine diphosphate; F ¼ force; P ¼ pressure; PMI ¼ periprocedural myocardial infarction;
TXA2 ¼ thromboxane A2.
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912strut activates a platelet-signaling pro-coagulation
pathway (Figure 2H), whereas the low shear stress
measured behind and between the strut induces
reversal of the ﬂow in a de-endothelialized area
(5-7) (Figure 2H). The magnitude of ﬂow disturbance
depends on the degree of protrusion of the strut into
the lumen. A low shear rate is known to induce
platelet aggregation, formation of microthrombiwith potential embolization, and micromyocardial
necrosis.
Although the clinical results and generating hypoth-
esis from the current study are intriguing, the result
should be cautiously interpreted and be conﬁrmed in a
randomized study, which is practically unexecutable
due to the unavailability of Cypher stent. In the future,
the new generation of bioresorbable scaffolds with a
FIGURE 2 Continued
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913thinner strut (100 mm) should be comparedwithmetallic
stents having a similar thickness.
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